Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
From Late-Line Rescue to Early-Line Option: The Potential for Bispecific Antibodies in Multiple Myeloma
María-Victoria Mateos, MD, PhD
Luciano Costa, M.D., Ph.D.
RAS Across Tumors: Who to Test When
Kathryn Arbour
Eileen M. O'Reilly, MD
Early Approaches to RAS Targeting: Efficacy Signals and Known Limitations
Unmet Need: Second-Line Outcomes Remain Poor for NSCLC and Pancreatic Cancer
NSCLC Data Review: Efficacy and Safety Data for ON-State RAS Inhibitors
Frontline Insights: Emerging Therapeutic Strategies in HNSCC
Kevin J Harrington, PhD, FRCP, FRCR, FRSB
Christophe Le Tourneau, MD, PhD
Severity Assessment: Can You Pin the Stage on the Patient?
Jennifer Geremia, PA-C
Brooke Hodnick, PA-C, MPAS
From Flare to Farewell: The IBD Care Playbook for Advanced Practice Providers
David Rubin, MD
Kimberly D. Orleck, PA-C
The New Era of RAS Targeting: Mechanisms, Evidence, and Clinical Integration of ON-State Inhibitors
Evaluating Use in Pancreatic Cancer: Efficacy and Safety Data for ON-State RAS Inhibitors
Breaking the Line: Moving Bispecific Antibodies Upstream in Treating Multiple Myeloma
Tailoring Treatment: Can You Select the Best Therapy?
Diagnosing IBD: Is It IBD or Something Else? Can You Tell?
IBD Immunopathogenesis: Do You Know What You're Blocking?
Advancing Bispecific Antibodies Upstream in the Treatment Paradigm of Multiple Myeloma
Advancing Care in HNSCC: Evolving Strategies Across the Disease Continuum
Cristina Rodriguez, MD
Case Review: Targets Are Met—Can You Stick the Landing?
Switching Strategies: Switch or Stay—What’s Your Call?
Treat-to-Target: Are We There Yet?
The Tumor That’s Not So Tiny: Understanding the Impact of TGCT
A.J. Gelderblom, MD, PhD
Mechanistic Evolution in RAS Therapy: ON-State and Multi-Selective Targeting
Case Review: Can You Crack This IBD Case?
When Topicals Fail: The New IPC Consensus Every Clinician Should Know
Linda Stein Gold, MD
Bruce Strober, MD, PhD
Implementing the Latest Diagnostic and Treatment Approaches for Generalized Myasthenia Gravis
Pushpa Narayanaswami, MD, FAAN
Beyond the Scalpel: When TGCT Surgery Isn’t the Solution
Michiel van de Sande, MD, PhD
Patient Perspective: Navigating TGCT Treatment—Surgery vs Systemic Therapy
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.